These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 30417253)

  • 21. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
    Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
    Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A systematic review of the barriers affecting medication adherence in patients with rheumatic diseases.
    Goh H; Kwan YH; Seah Y; Low LL; Fong W; Thumboo J
    Rheumatol Int; 2017 Oct; 37(10):1619-1628. PubMed ID: 28681249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can Educational Interventions Improve Osteoporotic Women's Adherence to Treatment? A Literature Review.
    Alvaro R; DʼAgostino F; Cittadini N; Zannetti EB; Rao C; Feola M; Vellone E; Pennini A; Tarantino U
    Orthop Nurs; 2015; 34(6):340-53; quiz 354-5. PubMed ID: 26575506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adherence to osteoporosis regimens among men and analysis of risk factors of poor compliance: a 2-year analytical review.
    Chiu CK; Kuo MC; Yu SF; Su BY; Cheng TT
    BMC Musculoskelet Disord; 2013 Sep; 14():276. PubMed ID: 24060442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osteoporosis medication adherence tools: a systematic review.
    Hesari E; Sanjari M; Mansourzadeh MJ; Fahimfar N; Khalagi K; Ghazbani A; Ostovar A; Fotouhi A
    Osteoporos Int; 2023 Sep; 34(9):1535-1548. PubMed ID: 37286664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims.
    Copher R; Buzinec P; Zarotsky V; Kazis L; Iqbal SU; Macarios D
    Curr Med Res Opin; 2010 Apr; 26(4):777-85. PubMed ID: 20095797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.
    Lee S; Glendenning P; Inderjeeth CA
    Osteoporos Int; 2011 Mar; 22(3):741-53. PubMed ID: 20589368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis.
    Saito T; Sterbenz JM; Malay S; Zhong L; MacEachern MP; Chung KC
    Osteoporos Int; 2017 Dec; 28(12):3289-3300. PubMed ID: 28770272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of prescribing and adherence patterns of anti-osteoporotic medications post-admission for fragility type fracture in an urban teaching hospital and a rural teaching hospital in Ireland between 2005 and 2008.
    McGowan B; Bennett K; Casey MC; Doherty J; Silke C; Whelan B
    Ir J Med Sci; 2013 Dec; 182(4):601-8. PubMed ID: 23483361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-adherence to anti-osteoporotic medications in Taiwan: physician specialty makes a difference.
    Yu SF; Yang TS; Chiu WC; Hsu CY; Chou CL; Su YJ; Lai HM; Chen YC; Chen CJ; Cheng TT
    J Bone Miner Metab; 2013 May; 31(3):351-9. PubMed ID: 23377623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening to Prevent Osteoporotic Fractures: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Viswanathan M; Reddy S; Berkman N; Cullen K; Middleton JC; Nicholson WK; Kahwati LC
    JAMA; 2018 Jun; 319(24):2532-2551. PubMed ID: 29946734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dispensing anti-osteoporotic drugs changed during the COVID-19 pandemic.
    Kocijan R; Stockinger T; Haschka J; Reichardt B; Resch H; Zwerina J; Behanova M
    Bone; 2022 Sep; 162():116477. PubMed ID: 35779846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison between bisphosphonates and other treatments for osteoporosis.
    Le Goff B; Guillot P; Glémarec J; Berthelot JM; Maugars Y
    Curr Pharm Des; 2010; 16(27):3037-44. PubMed ID: 20722614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of osteoporosis medications on fracture healing.
    Hegde V; Jo JE; Andreopoulou P; Lane JM
    Osteoporos Int; 2016 Mar; 27(3):861-871. PubMed ID: 26419471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adherence to osteoporosis medications amongst Singaporean patients.
    Cheen MH; Kong MC; Zhang RF; Tee FM; Chandran M
    Osteoporos Int; 2012 Mar; 23(3):1053-60. PubMed ID: 21503813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
    Lai PS; Chua SS; Chew YY; Chan SP
    J Clin Pharm Ther; 2011 Oct; 36(5):557-67. PubMed ID: 21916908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Examining the Effect of Medication Adherence on Risk of Subsequent Fracture Among Women with a Fragility Fracture in the U.S. Medicare Population.
    Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1178-1190. PubMed ID: 29083977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
    Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
    Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
    Moshi MR; Nicolopoulos K; Stringer D; Ma N; Jenal M; Vreugdenburg T
    Calcif Tissue Int; 2023 Jun; 112(6):631-646. PubMed ID: 37016189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.